Clinical Trials

In a remarkable leap forward for obesity treatment, Eli Lilly has revealed significant strides with orforglipron, an innovative oral GLP-1 receptor agonist targeting both obesity and diabetes. The announcement on August 26 showcases results from a pivotal Phase 3 clinical trial that have ignited

Welcome to an insightful conversation with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of technological innovation in the industry. Today, we dive into the groundbreaking advancements in RNA-based therapies,

Imagine a condition so rare and devastating that it not only compromises the body’s ability to repair DNA but also skyrockets the risk of cancer by 500 to 700 times compared to the general population, a reality for individuals with Fanconi anemia (FA). This genetic disorder often leads to bone

The realm of hemophilia treatment is witnessing a transformative wave, with innovative therapies challenging the status quo of managing this genetic blood clotting disorder, which has burdened patients for decades with frequent infusions to replace missing clotting factors. Now, a newly approved

I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, particularly in cutting-edge technologies and innovations in the industry. Today, we’re diving into a groundbreaking advancement in cancer treatment—a new formulation of

I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of technological innovation in the industry. Today, we’re diving into the recent European Commission approval of Cabometyx for advanced